M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia
about
Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Spine Enlargement of Pyramidal Tract-Type Neurons in the Motor Cortex of a Rat Model of Levodopa-Induced DyskinesiaCholinergic Interneurons Amplify Corticostriatal Synaptic Responses in the Q175 Model of Huntington's Disease.Maladaptive Synaptic Plasticity in L-DOPA-Induced DyskinesiaDiscovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine coreOptimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.Roles of centromedian parafascicular nuclei of thalamus and cholinergic interneurons in the dorsal striatum in associative learning of environmental events.Synaptic functions of endocannabinoid signaling in health and disease.Striatal cholinergic interneurons and Parkinson's disease.Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine ReleaseSpontaneous Synaptic Activation of Muscarinic Receptors by Striatal Cholinergic Neuron Firing.Physiological roles of CNS muscarinic receptors gained from knockout mice.Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.A Feedforward Inhibitory Circuit Mediated by CB1-Expressing Fast-Spiking Interneurons in the Nucleus Accumbens.Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning.Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.Levodopa treatment and dendritic spine pathology.Striatal synapses, circuits, and Parkinson's disease.Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.Basal ganglia mechanisms in action selection, plasticity, and dystonia.Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.Kainate Receptors Inhibit Glutamate Release Via Mobilization of Endocannabinoids in Striatal Direct Pathway Spiny Projection Neurons.The striatal cholinergic system in L-dopa-induced dyskinesias.Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor.Pauses in cholinergic interneuron firing exert an inhibitory control on striatal output in vivo.Inhibition of basal and amphetamine-stimulated extracellular signal-regulated kinase (ERK) phosphorylation in the rat forebrain by muscarinic acetylcholine M4 receptors.
P2860
Q26768220-DF92ECF9-7BF3-4B85-A4C5-5EC2A2EF515DQ33559375-372A09ED-D5B0-49C1-ABCE-358FCA510219Q37507773-E128951D-1062-484A-96BA-958492AF569CQ37516434-45B2A9A8-DFAB-4328-A581-D4F3568D1A92Q38436762-11C4E1DA-8137-4146-8B3A-50F077DA197DQ38437959-A12EF514-A87D-4A37-BDB2-557CFC00263FQ38820286-40F852E1-DE79-49FE-AAC1-34B584EC13BDQ39067400-722EB53B-0E6D-4CAD-AFC9-38053CE012ABQ39190510-8F46406D-D30F-4629-BEC6-475C719D1F4CQ39381131-CE272763-D416-4261-8A0E-5C9FF3774F34Q39414543-2D4A1DF0-35C1-440D-8CA6-8F017AA27EECQ41159357-0538DDA2-82ED-43F4-9A43-53810628EC15Q42330741-1CF6E745-A9E4-41A8-A195-0A684377319BQ43076051-4C07BC92-6032-428C-8B49-46AD836FF7D5Q46145089-E5D8B3F0-3C0F-4B13-8E3F-DFE3E963EBCEQ46447901-E62A4E3E-F7AA-401A-A09C-4B5A6529DBBEQ47378768-67D67809-8FD0-4F49-A605-C40288EC3A46Q47563473-02880FE8-CAD5-425A-897D-146F4B8CD5A6Q47644788-1A68CCDD-01B4-4E95-9AEF-A6AD95A48793Q47864774-3856444C-06E5-4677-BE47-9C50E723531DQ47909580-797968A9-40CC-4D3E-8925-3809A291F40CQ48113066-2574A615-72E0-40C8-ADC5-335A1393C675Q48138673-1F9F97F5-9A44-4937-B625-DBE35D1D10CEQ48177380-5AF03AF8-31D9-489B-AB1B-FE884F41DC8CQ48631361-D58620DC-41A6-4551-A065-611A1F7A099DQ49361175-608AF65C-DC34-48FC-9E41-5A89B281DE0BQ50993859-EC706108-E721-41E1-8DD1-07E93ABE4051Q52655473-410BFC0C-CF11-4AA4-BDA7-3DED04EA42D5Q52680310-9F1CFEE9-4006-4732-8E05-731F0E94F07EQ52740407-37FE88E3-A3E8-4CCD-B779-8CB543D4875FQ54936284-270F9330-2F2B-43BE-B7DC-7BA00926DB1EQ54981672-E49CD76D-90DC-4BB9-9C21-98A927DF964E
P2860
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
M4 Muscarinic Receptor Signali ...... s of L-DOPA-Induced Dyskinesia
@en
type
label
M4 Muscarinic Receptor Signali ...... s of L-DOPA-Induced Dyskinesia
@en
prefLabel
M4 Muscarinic Receptor Signali ...... s of L-DOPA-Induced Dyskinesia
@en
P2093
P2860
P50
P1433
P1476
M4 Muscarinic Receptor Signali ...... s of L-DOPA-Induced Dyskinesia
@en
P2093
D James Surmeier
Jürgen Wess
M Angela Cenci
Richard R Neubig
Tim Fieblinger
Wai Kin D Ko
Weixing Shen
P2860
P304
P356
10.1016/J.NEURON.2015.10.039
P407
P577
2015-11-01T00:00:00Z